Kinase News and Research

RSS

Genetic variations influence risk for developing choline deficiency symptoms

What is now considered to be the "right" amount of the essential nutrient, choline, might actually be "wrong," depending on who you are. That's because scientists have found that the "right" amount of choline needed by an individual is influenced by a wide range of factors, including gender, life stage, race and ethnicity of the individual.

29 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

New era of lung cancer therapy close to dawning

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

27 Mar 2014

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

25 Mar 2014

New research reveals new complexity to nerve cells in brain that could affect future therapies

Research from the Oklahoma Medical Research Foundation reveals a new complexity to nerve cells in the brain that could affect future therapies aimed at altering mood and memory in humans.

25 Mar 2014

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

Two studies are providing new insight into germline epidermal growth factor receptor (EGFR) T790M mutation in familial non-small cell lung cancer (NSCLC). The findings suggest the need for tailored approaches for early detection and treatment, as well as for genetic testing to identify carriers.

24 Mar 2014

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Genomic fusion testing for echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase genes plus targeted first-line crizotinib is not a cost effective treatment strategy for patients with advanced non-squamous non-small-cell lung cancer, shows a Canadian analysis.

20 Mar 2014

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects but also improves a patient's life expectancy and quality of life.

20 Mar 2014

Researchers discover potential new therapeutic target for controlling high blood sugar

A UT Southwestern Medical Center study has identified a new potential therapeutic target for controlling high blood sugar, a finding that could help the estimated 25 million Americans with type 2 diabetes.

19 Mar 2014

Nine fellows selected to receive Dennis Weatherstone Predoctoral Fellowship for next two years

Autism Speaks, the world's leading autism science and advocacy organization, today announced the sixth class of The Dennis Weatherstone Predoctoral Fellows funded by the Stavros Niarchos Foundation.

19 Mar 2014

Researcher discover new chemical class that attacks two key cancer cell building block targets

Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

14 Mar 2014

Scientists discover new protein that drive metastasis of cancer cells

An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body.

11 Mar 2014

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

10 Mar 2014

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.

10 Mar 2014

Researchers develop new technique to map interactions between proteins at heart of many diseases

Researchers at the UNC School of Medicine have devised a new biochemical technique that will allow them and other scientists to delve much deeper than ever before into the specific cellular circuitry that keeps us healthy or causes disease.

10 Mar 2014

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

4 Mar 2014

Researchers find unusual mutation strongly linked to rare liver cancer that affects teens

In the race for better treatments and possible cures, rare diseases are often left behind. In a collaboration of researchers at The Rockefeller University, Memorial Sloan Kettering Cancer Center and the New York Genome Center (NYGC), an unusual mutation has been found that is strongly linked to one such disease: a rare liver cancer that affects teens and young adults.

3 Mar 2014

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Non-small-cell lung cancer patients with very unusual epidermal growth factor receptor mutations may be more likely to be benefit from first-line chemotherapy than a tyrosine kinase inhibitor, research suggests.

25 Feb 2014

Novel two-pronged strategy targeting DNA synthesis treats leukemia in mice

A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice, according to a study in The Journal of Experimental Medicine.

25 Feb 2014

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

21 Feb 2014

Kinase News and Research

Genetic variations influence risk for developing choline deficiency symptoms

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

New era of lung cancer therapy close to dawning

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

New research reveals new complexity to nerve cells in brain that could affect future therapies

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Researchers discover potential new therapeutic target for controlling high blood sugar

Nine fellows selected to receive Dennis Weatherstone Predoctoral Fellowship for next two years

Researcher discover new chemical class that attacks two key cancer cell building block targets

Scientists discover new protein that drive metastasis of cancer cells

A pill may provide hope to relapsed leukemia and lymphoma patients

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

Researchers develop new technique to map interactions between proteins at heart of many diseases

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Researchers find unusual mutation strongly linked to rare liver cancer that affects teens

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Novel two-pronged strategy targeting DNA synthesis treats leukemia in mice

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News